New whole-body multimodality imaging of gastric cancer peritoneal metastasis combining fluorescence imaging with ICG-labeled antibody and MRI in mice
Authors:
- Yuichi ItoYIYuichi Ito
- Shigeru MatsushimaSMShigeru Matsushima
- Daisuke TsuchidaDTDaisuke Tsuchida
- Mai OgasawaraMOMai Ogasawara
- Junichi HasegawaJHJunichi Hasegawa
- Kazunari MisawaKMKazunari Misawa
- Eisaku KondoEKEisaku Kondo
- Norio KanedaNKNorio Kaneda
- Hayao NakanishiHNHayao Nakanishi
Open Access
- 28 November 2013
- journal article
- research article
- Published by Springer Nature in Gastric Cancer
- Vol. 17 (3) , 497-507
Abstract
Peritoneal metastasis is the most frequent pattern of recurrence after curative surgery for gastric cancer. However, such a recurrence is difficult to detect by conventional computed tomography (CT) and magnetic resonance imaging (MRI) at an early stage. To improve the sensitivity and specificity of diagnostic imaging for peritoneal metastasis, we developed a new type of multimodality imaging combining fluorescence imaging with near-infrared fluorophore (NIR)-labeled antibodies and MRI. Dual optical imaging of peritoneal metastasis was carried out using luciferase-tagged gastric cancer cell lines and XenoLight CF750 or indocyanine green (ICG)-labeled anti-human epidermal growth factor receptor (EGFR) or CEA antibody as a probe in mice with Ivis in vivo imaging system. This whole-body fluorescent imaging system sensitively detected metastatic foci <1 mm in diameter in the peritoneal cavity noninvasively. Fluorescence imaging proved to be specific because the fluorescence signal was abolished by blocking with excess unlabeled antibody. Although this fluorescence imaging had higher sensitivity for detection of small-sized peritoneal metastases than MRI, it proved difficult to accurately determine organ distribution of the metastasis. We thus developed a multimodality imaging system by the fusion of the three-dimensional fluorescence image with the MRI image and demonstrated its improved diagnostic accuracy over either method alone. The present results suggest that multimodality imaging consisting of fluorescence imaging with NIR-labeled EGFR or CEA antibody and MRI allows sensitive, specific, and anatomically accurate detection of peritoneal metastasis noninvasively at an early stage.Keywords
This publication has 29 references indexed in Scilit:
- The EGFR Ligands Amphiregulin and Heparin-Binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-Expressing Gastric CancerClinical Cancer Research, 2011
- Performance characterization of the Inveon preclinical small-animal PET/SPECT/CT system for multimodality imagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell CarcinomaClinical Cancer Research, 2010
- Peritoneal Metastasis: Detection with 16– or 64–Detector Row CT in Patients Undergoing Surgery for Gastric CancerRadiology, 2009
- Molecular Imaging of Therapeutic Response to Epidermal Growth Factor Receptor Blockade in Colorectal CancerClinical Cancer Research, 2008
- Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancerOncogene, 2007
- A Photon Counting Technique for Quantitatively Evaluating Progression of Peritoneal Tumor DisseminationCancer Research, 2006
- Establishment and characterization of three novel human gastric cancer cell lines with differentiated intestinal phenotype derived from liver metastasisClinical & Experimental Metastasis, 2005
- Green fluorescent protein imaging of tumour growth, metastasis, and angiogenesis in mouse modelsThe Lancet Oncology, 2002
- Rapid quantitative detection of carcinoembryonic antigen-expressing free tumor cells in the peritoneal cavity of gastric-cancer patients with real-time RT-PCR on the lightcyclerInternational Journal of Cancer, 2000